All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ClearPoint Neuro, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Joseph Burnett, all published on March 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Joseph Burnett
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention ClearPoint Neuro, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Joseph Burnett, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Joseph Burnett. Shared-story counts are live from our verified record — not editorial picks.
ClearPoint Neuro (CLPT) achieved record full-year 2025 revenue of $37 million, driven by a 23% fourth-quarter surge in its Biologics and Drug Delivery segment. The company is pivoting toward a higher-growth profile through the integration of Eris Holdings and IRRAS, setting an ambitious revenue target of up to $56 million for 2026.
Joseph Burnett is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.